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Background & Aims—Patients with inflammatory bowel diseases (IBD) have increased risk 
for venous thromboembolism (VTE); those who require hospitalization have particularly high risk. 
Few hospitalized patients with IBD receive thromboprophylaxis. We analyzed the frequency of 
VTE following IBD-related hospitalization, risk factors for post-hospitalization VTE, and the 
efficacy of prophylaxis in preventing post-hospitalization VTE.
Methods—In a retrospective study, we analyzed data from a multi-institutional cohort of patients 
with Crohn's disease or ulcerative colitis and at least 1 IBD-related hospitalization. Our primary 
outcome was a VTE event. All patients contributed person time from the date of the index 
hospitalization to development of VTE, subsequent hospitalization, or end of follow-up. Our main 
predictor variable was pharmacologic thromboprophylaxis. Cox proportional hazard models 
adjusting for potential confounders were used to estimate hazard ratios (HR) and 95% confidence 
intervals (CI).
Results—From a cohort of 2788 patients with at least 1 IBD-related hospitalization, 62 patients 
developed VTE following discharge (2%). Incidences of VTE at 30, 60, 90, and 180 days after the 
index hospitalization were 3.7/1000, 4.1/1000, 5.4/1000, and 9.4/1000 person-days respectively. 
Pharmacologic thromboprophylaxis during the index hospital stay was associated with a 
significantly lower risk of post-hospitalization VTE (HR, 0.46; 95% CI, 0.22–0.97). Increased 
numbers of co-morbidities (HR, 1.30; 95% CI, 1.16–1.47) and need for corticosteroids before 
hospitalization (HR 1.71, 95% CI 1.02 –2.87) were also independently associated with risk of 
VTE. Length of hospitalization or surgery during index hospitalization was not associated with 
post-hospitalization VTE.
Conclusions—Pharmacologic thromboprophylaxis during IBD-related hospitalization is 
associated with reduced risk of post-hospitalization VTE.
Keywords
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INTRODUCTION
Patients with inflammatory bowel diseases (IBD; Crohn's disease (CD), ulcerative colitis 
(UC)) are at increased risk for venous thromboembolism (VTE)1–7 and associated morbidity 
and mortality2, 6. Inflammation is key determinant of VTE risk in IBD with ambulatory 
flares and hospitalization being associated with increased risk 1, 2, 5, 6. As the absolute VTE 
risk is greatest during hospitalization, experts recommend routine thromboprophylaxis in 
such settings6, 8. However, despite the safety and efficacy of thromboprophylaxis, the rate of 
adoption remains low9, 10.
In other settings at high-risk for VTE such as following orthopedic surgery, the risk remains 
elevated for several weeks due to persistence of risk factors such as limited mobility11. 
Conceivably, patients with IBD who have a severe disease flare requiring hospitalization 
remain at an elevated risk for VTE till inflammation resolves. Routine extended 
thromboprophylaxis is widely used following orthopedic surgery 11 but is not beneficial in 
general medical inpatients12. Prophylaxis during all ambulatory IBD flares may not be cost-
effective13 but identification of subgroups of patients at a higher VTE risk may define those 
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who could potentially experience greater benefit with extended thromboprophylaxis. 
Furthermore, the impact of thromboprophylaxis during hospitalization on subsequent risk of 
VTE has not been examined previously.
Using a large multi-institutional cohort of IBD patients, our aims were to (i) examine the 
frequency of VTE following an IBD-related hospitalization; (ii) identify risk factors for 
post-hospitalization VTE events; and (iii) define the use of thromboprophylaxis in an 
inpatient IBD population and examine its impact on subsequent risk of VTE.
METHODS
Study Population
The data source for our study was an electronic medical record cohort of patients with CD 
and UC which has described in our previous publications14–17. From a multi-hospital 
healthcare system in the Greater Boston area serving a population of over 3 million patients, 
we identified all potential IBD patients by the presence of at least one international 
classification of diseases, 9th edition, clinical modification (ICD-9-CM) code for CD (555.x) 
or UC (556.x). We extracted a range of codified data encompassing manifestations 
indicating severity or disease-related complications. From our electronic prescription 
system, we also extracted information on whether the patients had ever been prescribed 
medications used in the treatment of IBD including corticosteroids, 5-aminosalicylates, 
immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), or anti-tumor necrosis 
factor biologic agents (anti-TNF) (infliximab, adalimumab, certolizumab pegol). We then 
extracted narrative free-text concepts identified using natural language processing (NLP) 
with the clinical Text Analysis and Knowledge Extraction System (cTAKES)18 as outlined 
in our previous publications. These could include terms such as “Crohn's disease” 
“ulcerative colitis”, phrases used in endoscopic reports such as (“aphthous ulcers”), 
radiology (“ileal wall thickening”), or pathology reports (“ileitis”). We then developed an 
algorithm using logistic regression with adaptive lasso to identify variables that predicted a 
diagnosis of CD or UC. This assigned each patient a probability between 0 and 1 of truly 
having CD or UC. We selected a cutoff for classifying disease that corresponded to a 
positive predictive value of 97%. The final algorithm was validated in an independent subset 
of patients and when applied to the entire population of potential patients, yielded our final 
IBD cohort of 5,522 UC and 5,506 CD patients.
Cases of venous thromboembolism were identified by the presence of validated ICD-9 codes 
for deep venous thrombosis, pulmonary embolism, intra-abdominal or portal thrombosis, 
and other thrombotic events such as cerebral thrombosis (ICD-9-CM 415.1, V125.1, 451.1–
451.8, 453.0–453.9, 671.5, 325.0, 437.6, 671.9)2, 4, 19, 20. All VTE events were classified as 
occurring while inpatient or outpatient, and where this distinction was not possible, the 
events were labeled unclassified.
Variables
We extracted the patients' age including age at first diagnosis code for either CD or UC, 
gender, race (white or non-white), and defined co-morbidity using the validated Charlson 
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co-morbidity index21. We determined the occurrence of IBD-related hospitalizations or 
surgeries using the primary reason for discharge among hospitalized patients. Medication 
use was defined as ever or never use prior to the event of interest. We also ascertained 
whether a patient had received a diagnosis of solid organ or metastatic tumor prior to the 
index hospitalization.
Primary analysis – Predictors and Outcomes
Our primary analysis focused on occurrence of post-hospitalization VTE in adult IBD 
patients who had an IBD-related hospitalization or surgery. After excluding 22 patients who 
were on coumadin at the time of the index hospitalization, we arrived at a final cohort of 
2,788 patients with CD or UC. Our main outcome variable was time to an outpatient VTE 
event. Patients who developed thrombosis during the initial hospitalization or during a 
subsequent hospitalization were excluded. Our main predictor of interest was receipt of 
venous thromboprophylaxis, namely the use of unfractionated heparin, enoxaparin, or 
dalteparin. We classified use of IBD-related medications as those occurring prior to the 
index hospitalization and extracted information on the duration of hospitalization and if it 
was related to a surgical procedure. In a subset of patients where this was available, we 
obtained information on the most recent laboratory markers of disease severity at the time of 
the index hospitalization including hemoglobin, albumin, serum creatinine, erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), platelet count and white blood cell 
count.
Statistical analysis
Analysis was performed using Stata 12.0 (StataCorp, College Station, TX). Continuous 
variables were summarized using medians and interquartile ranges (IQR); categorical 
variables were expressed as proportions and compared using the chi-square test. All patients 
contributed person time from the date of the index hospitalization (either medical or 
surgical) to development of VTE, subsequent hospitalization or surgery, or end of follow-up 
within our EMR. We used a Cox proportional hazards model and entered variables meeting 
statistical significance at a threshold of p < 0.10 into our final multivariate model. 
Independent predictors were considered significant if the two-sided p-value was ≤ 0.05. All 
models satisfied the proportionality of hazards assumption. Our study was approved by the 
institutional review board of Partners Healthcare.
RESULTS
From our initial IBD cohort of 5,506 patients with CD and 5,522 with UC, 760 (7%) had at 
least one VTE event (Figure 1). Of these, 431 were inpatient, 276 outpatient, and for 53 
VTE events, we were unable to determine admission status at the time of the event. IBD 
patients who had a VTE event were older, had a greater Charlson co-morbidity index, and 
were more likely to have had an IBD-related hospitalization or surgery than those who did 
not develop VTE (p < 0.001) (Table 1). Patients who developed inpatient VTE were similar 
to those with outpatient VTE. Over a median follow-up of 10 years, 7% of patients without 
VTE died compared to 18% of those with outpatient VTE and 27% of those with an 
inpatient VTE event (p < 0.001).
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Three variables were independent predictors of a VTE event (Table 2). An IBD-related 
hospitalization was the strongest risk factor for VTE (Odds ratio (OR) 1.72, 95% confidence 
interval (CI) 1.39 – 2.12). Each additional co-morbidity included in the Charlson score was 
associated with an independent increase in risk of VTE (OR 1.43, 95% CI 1.36 – 1.50) and 
each year increase in age was associated with a 2% increase in risk (Odds ratio (OR) 1.02, 
95% confidence interval (CI) 1.02 – 1.03).
For our primary analysis, we utilized a cohort of 2,788 patients with an IBD-related 
hospitalization. Among them, 62 patients (2%) developed VTE, 3 of which were pulmonary 
emboli, 2 were intra-abdominal thromboses and the remaining were deep venous thrombosis 
events. The incidence of VTE at 30, 60, 90, and 180 days after the index hospitalization was 
3.7/1000, and 4.1/1000, 5.4/1000, and 9.4/1000 respectively. Table 3 presents the results of 
the univariate and adjusted models examining predictors of post-hospitalization VTE. 
Increasing co-morbidity (Hazard ratio (HR) 1.30, 95% CI 1.16 – 1.47) was an independent 
predictor of post-hospitalization VTE. Use of corticosteroids prior to the hospitalization was 
independently associated with risk of VTE (HR 1.71, 95% CI 1.02 – 2.87). Length of 
hospitalization or whether index hospitalization was related to surgery was not predictive of 
subsequent VTE. In the hospitalized cohort, 788 patients (28.3%) were administered 
pharmacologic thromboprophylaxis. Interestingly, receiving thromboprophylaxis during the 
hospitalization was associated with a significantly lower risk of post-hospitalization VTE 
(HR 0.46, 95% CI 0.22 – 0.97) (Figure 2). This effect was greater for VTE that occurred 
within 90 days (HR 0.19, 95% CI 0.02 – 1.48) than those occurring 90 days or more after 
the hospitalization (HR 0.52, 95% CI 0.23 – 1.17).
Since recent laboratory markers were available on only a subset of patients, we performed 
an exploratory analysis of their utility in predicting post-hospitalization VTE. Each 1g/dL 
increase in serum albumin was associated with a reduced risk of VTE (HR 0.66, 95% CI 
0.42 – 1.05) while greater serum creatinine was associated with an increased risk (HR 1.34, 
95% CI 1.14 – 1.58). The risk of VTE at 30 days in patients with a low albumin on 
hospitalization was 10/1000 person-days compared to those with normal serum albumin who 
had a risk of 5/1000 person-days (p < 0.05). C-reactive protein, ESR, platelet count or WBC 
count at hospitalization were not predictive of subsequent VTE risk. Recognizing that 
patients with severe disease and rectal bleeding may be considered to be at higher bleeding 
risk from thromboprophylaxis despite their higher VTE risk, we adjusted for hemoglobin at 
the time of hospitalization. While only 19% of patients with hemoglobin below 10g/dL 
received thromboprophylaxis compared to 32% of patients with a value ≥ 10g/dL (p < 0.05), 
hemoglobin level, anemia, or blood transfusion were not in themselves predictive of post-
discharge VTE and did not alter the association between thromboprophylaxis and VTE.
DISCUSSION
Using a large IBD cohort, we demonstrate that a substantial fraction of VTE events in IBD 
patients occurs in the outpatient setting. Among patients with an IBD-related hospitalization, 
the risk of VTE within 180 days after hospitalization was significantly higher in those with 
older age, greater co-morbidity burden or who required steroids prior to hospitalization. 
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Receiving thromboprophylaxis during the hospitalization was associated with a reduced risk 
of post-discharge VTE.
Prior studies have examined risk factors for VTE in IBD patients. Inherited thrombophilias 
have not been consistently associated with the initial or recurrent VTE3, 6, 22, 23. In a prior 
study, age and co-morbidity were both associated with increased risk of VTE, consistent 
with our results2. Disease activity has also been consistently associated with increased VTE 
risk5. In the study by Grainge et al., the absolute risk was lower among non-hospitalized 
patients (6.4 per 1000 person-years) compared to hospitalized patients (37.5 per 1000 
person-years)5. The risk of VTE in the post-hospitalization period was similar to ambulatory 
disease flares, and higher than that for IBD overall reported from previous cohort studies1, 4.
We found systemic steroids to be associated with increased risk of post-hospitalization VTE. 
While this, in part, likely reflects the association between inflammation and VTE, other 
studies have suggested that use of steroids in itself could be a risk factor for VTE. In a large 
cohort study, systemic glucocorticoids use was associated with a two-fold increase in risk 
for VTE24 and oral glucocorticoids were associated with an increased risk of PE particularly 
within the first 30 days of use though the elevation in risk persisted for 1 year25. Low serum 
albumin is a well recognized risk factor for VTE in nephrotic syndrome26 and chronic liver 
disease27. Even in the general population, low serum albumin may be associated with a 
modest increase in risk of VTE28. Prior studies on VTE risk in IBD have been limited by 
lack of laboratory data to examine this association. Low albumin levels may reflect excess 
loss of protein, and in particular, circulating anti-thrombotic proteins. It may be a marker of 
underlying inflammation as a negative acute phase reactant. Finally, low albumin may be 
associated with chronic illness and associated prothrombotic risk factors such as reduced 
mobility.
The most important finding of our study was that in-hospital thromboprophylaxis was 
associated with a reduced risk of post-discharge VTE. Despite widespread 
acknowledgement of the increased risk for venous thrombosis in IBD, rates of 
thromboprophylaxis remain low10, 29. In a large practice survey, only 35% of 
gastroenterologists indicated routine use of VTE prophylaxis in hospitalized patients with 
severe UC29. The rates of VTE prophylaxis are higher among surgical compared to medical 
inpatients9, 10. There are a few mechanisms through which thromboprophylaxis in-hospital 
may reduce risk of post-discharge VTE. First, some of the thrombosis events identified in 
the group not receiving thromboprophylaxis may have been present at the time of 
hospitalization but become apparent only after discharge, explaining the protective effect of 
in-hospital prophylaxis. Second, prior clinical trials have demonstrated that unfractionated 
heparin itself may be beneficial in the treatment of some patients with active ulcerative 
colitis and Crohn's disease30, 31. Since one key mechanism underlying VTE risk in patients 
with IBD is the inflammatory burden, it is plausible that some of the anti-inflammatory 
effects of heparin may aid in earlier or more substantial resolution of the circulating 
inflammatory burden in the cohort receiving thromboprophylaxis. The fact that the 
protective effect is strongest within 1–3 months after discharge is consistent with such short 
term mechanisms of effect.
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Whether the occurrence of post-hospitalization VTE translates to need for extended 
thromboprophylaxis in hospitalized IBD patients is unclear. Only few studies have 
examined the effect of extended thromboprophylaxis. In a series following patients 
undergoing major surgery, between 2–5% of patients experienced a VTE within 30 days of 
discharge suggesting there may be benefit to extended prophylaxis32, 33. In contrast, Fanikos 
et al. found no difference in the 90 day VTE rate between general medical inpatients who 
received extended prophylaxis after discharge compared to in-hospital prophylaxis only12. 
In a systematic review, extended thromboprophylaxis with LMWH heparin was effective in 
reducing risk of major VTE events in high-risk patients34.
There are several implications to our findings. As the absolute risk of VTE following 
hospitalization was lower in our cohort than in the post-surgical literature, it is unlikely that 
extending thromboprophylaxis in IBD patients will be cost-effective. In a recent decision 
analysis, though pharmacologic VTE reduced lifetime risk of VTE, it was not associated 
with a significant improvement in quality-adjusted life years13. However, identification of 
high-risk subgroups may allow targeting studies of extended prophylaxis in IBD to those at 
highest risk of post-discharge VTE. In the meantime, in-hospital prophylaxis appears to not 
only protect during VTE events associated with the hospitalization but also early post-
hospitalization VTE. Consequently, continued attempt to improve rates of prophylaxis is 
important. There are infrequent risks associated with thromboprophylaxis including bleeding 
risk and heparin induced thrombocytopenia. While such risks should be incorporated into 
personalized decision making, they are of lower magnitude than the risk of VTE.
We acknowledge several limitations to our study. First, the two main hospitals contributing 
to our patient cohort are both referral hospitals, biasing our cohort towards severe disease. 
However, as this is the group at the highest risk of VTE, it represents an important patient 
population for study. Second, identification of VTE was triggered by symptoms. However, 
recent studies have demonstrated that asymptomatic DVT is uncommon in hospitalized 
patients with IBD35. Third, we examined thromboprophylaxis use as a dichotomous 
variable. Further studies with greater detail may be better suited to examine the effect of 
dose or duration of VTE prophylaxis on risk of subsequent VTE. Finally, we analyzed only 
the first VTE event to retain homogeneity and to ensure that all patients were potentially 
eligible to receive pharmacologic thromboprophylaxis. Future studies should examine the 
impact of prior VTE on the risk of recurrence post-hospitalization.
In conclusion, we demonstrate that a substantial fraction of VTE events in IBD patients 
occur in the outpatient setting. Subgroups of patients including those with older age, greater 
co-morbidity, and need for systemic steroids are at greater risk for VTE post-discharge. 
Pharmacologic thromboprophylaxis during hospitalization is associated with reduced risk of 
post-hospitalization VTE. Consequently, it is important to increase adoption of 
thromboprophylaxis routinely in the hospitalized IBD patient while exploratory studies of 
extended thromboprophylaxis should be targeted to those with additional risk factors.
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Figure 1. 
Flowchart demonstrating ascertainment of cases and outcomes
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Figure 2. 
Effect of venous thromboprophylaxis on post-hospitalization venous thromboembolic events
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Table 2
Multivariate analysis of predictors of venous thromboembolism
Characteristic Odds Ratio 95% confidence interval
Age (in years) 1.02 1.02 – 1.03
Female 1.08 0.91 – 1.28
Non-white race 0.84 0.71 – 1.01
Modified Charlson score 1.43 1.36 – 1.50
Cancer diagnosis 1.24 0.93 – 1.66
IBD hospitalization 1.72 1.39 – 2.12
IBD surgery 1.22 0.95 – 1.58
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